A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours [PDF]
, 2009 PURPOSE: To evaluate the safety, efficacy and pharmacokinetics of imatinib in children with recurrent or refractory central nervous system (CNS) tumours expressing KIT and/or PDGFRA.
Bartels, Ute +9 more
core +1 more source
Indian Journal of Medical and Paediatric Oncology, 2013 Post Graduate Institute (PGI) Chandigarh is a premier institute of North India. There are approximately 70,000 admissions per year. The adult clinical hematology department sees more than 2000 new patients per year.
Pankaj Malhotra +2 more
doaj +1 more source
Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta [PDF]
, 2002 Jane F. Apperley +18 more
openalex +1 more source
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. [PDF]
, 2013 PurposeDasatinib is a prototypic short half-life BCR-ABL1 tyrosine kinase inhibitor. The recommended dose of dasatinib for chronic myeloid leukemia in chronic phase was changed from 70 mg twice daily to 100 mg once daily following a Phase III dose ...
Chen, Tai-Tsang +5 more
core +2 more sources
Imatinib Mesylate in Cutaneous Melanoma [PDF]
Journal of Investigative Dermatology, 2004 Enrique J. Andreu +3 more
openaire +3 more sources
Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate. [PDF]
Gels, 2023 Jitrangsri K +4 more
europepmc +1 more source
Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia [PDF]
, 2002 Hendrik W. van Deventer +8 more
openalex +1 more source
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis [PDF]
, 2017 Tissue fibrosis is a major cause of death in SSc, but therapies that target selectively fibrosis are not yet available for routine clinical use. Recent pre-clinical studies suggest that selective tyrosine kinase inhibitors that target c-Abl, PDGF ...
Distler, J. H. W., Distler, O.
core
BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90 [PDF]
, 2002 M. Gorre +4 more
openalex +1 more source
Prospects for non-immunological molecular therapeutics in melanoma [PDF]
, 2010 In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Crown, John +4 more
core